OCT2 and MATE1 Inhibition by Antiemetics

Renal drug secretion is not simply a passive filtration process. For many organic cations, transport across the proximal tubule involves coordinated uptake from blood through organic cation transporter 2 (OCT2) and subsequent extrusion into the tubular lumen through multidrug and toxin extrusion protein 1 (MATE1). The study by George and colleagues, In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs, examines whether commonly used 5-HT3 receptor antagonists interfere with this pathway.

The work is relevant to pharmacokinetics, renal toxicology, and drug–drug interaction assessment because the tested antiemetics are cationic compounds themselves. Rather than treating the drug class as pharmacologically uniform, the authors measured transporter-specific effects and then asked whether inhibition observed in isolated uptake assays translated into impaired directional secretion across a cell monolayer.

Study Background and Research Question

OCT2 is positioned on the basolateral membrane of renal tubular epithelial cells, where it contributes to uptake of organic cations from the circulation. MATE1 is located toward the apical, brush-border membrane and helps move these compounds into the forming urine. Efficient secretion therefore depends on the functional cooperation of both transporters. Disruption at either step can increase intracellular or systemic exposure to a cationic drug.

5-HT3 antagonists are widely used to prevent nausea and vomiting associated with chemotherapy, radiation, and surgery. The class includes ondansetron, granisetron, tropisetron, dolasetron, and palonosetron. Earlier evidence had suggested that some members, particularly ondansetron and tropisetron, could interact with organic cation transporters. The central question in the reference study was whether all five agents inhibit human OCT2 and MATE1, and whether their effects differ between transporter uptake and overall transepithelial secretion.

This distinction matters. A compound may inhibit OCT2 more strongly than MATE1, affect only one transporter, or produce a measurable effect in an uptake assay without substantially changing net epithelial transport. The study was designed to separate these possibilities rather than infer renal secretion effects from a single screening endpoint.

Key Innovation from the Reference Study

The principal innovation is the integration of transporter-selective and pathway-level experiments. The authors first measured inhibition of a probe substrate in cells overexpressing OCT2 or MATE1 separately. They then used a polarized MDCK model expressing both transporters to evaluate basolateral-to-apical movement, a closer in vitro approximation of vectorial renal secretion.

This design provides two complementary types of information. The HEK293 experiments estimate the relative susceptibility of each transporter to each antiemetic, while the double-transfected MDCK system tests whether those interactions alter the direction and extent of substrate passage through an epithelial barrier. The approach also reveals that transporter interaction is compound-specific: the strongest OCT2 inhibitor was not the strongest MATE1 inhibitor.

According to the reference study, palonosetron was the most potent inhibitor of OCT2, whereas ondansetron was the most potent inhibitor of MATE1. That divergence is an important mechanistic finding because it argues against using activity of one transporter as a proxy for the entire renal secretion pathway.

Methods and Experimental Design Insights

The investigators used the fluorescent organic cation ASP+ as a probe substrate. Uptake was assessed in HEK293 kidney cells engineered to overexpress human OCT2 or human MATE1. This format enabled direct comparison of inhibitor potency at each transporter while reducing the confounding contribution of unrelated endogenous transport processes.

A second model used MDCK cells transfected with both human OCT2 and MATE1. In this polarized system, the researchers measured basolateral-to-apical transcellular transport of ASP+ and examined intracellular accumulation. The combined model is particularly useful for studying directional secretion because it incorporates sequential transporter activity rather than evaluating uptake in isolation.

Protocol Parameters

• Probe substrate: ASP+ was used to monitor organic cation transport in the OCT2- and MATE1-expressing cell systems, according to the published study.
• Transporter-specific screening: HEK293 cells overexpressing human OCT2 or MATE1 were analyzed separately to derive inhibitor concentration–response relationships.
• Test panel: The study evaluated five 5-HT3 antagonists: ondansetron, palonosetron, granisetron, tropisetron, and dolasetron.
• Directional transport: In the double-transfected MDCK model, ASP+ movement was assessed from the basolateral to the apical compartment to represent net epithelial secretion.
• Ondansetron range: Ondansetron was tested from 0.5 to 20 μM in the transcellular transport experiments, and inhibition reached as much as 64% in that assay, as reported in the reference paper.
• Additional concentration points: Palonosetron, tropisetron, and dolasetron produced comparable reductions in transcellular transport at the higher tested concentrations of 10 and 20 μM.

These parameters should be interpreted as study-specific experimental conditions rather than universal assay settings. For replication, transporter expression level, cell passage history, monolayer integrity, probe-substrate concentration, incubation time, and analytical normalization would all need to be controlled. A useful workflow is to confirm transporter function with appropriate positive controls before comparing antiemetic inhibition profiles.

Core Findings and Why They Matter

In OCT2-expressing HEK293 cells, palonosetron showed the greatest inhibitory potency, with an IC50 of 2.6 μM. The potency sequence was palonosetron, ondansetron, granisetron, tropisetron, and dolasetron, with dolasetron showing an IC50 of 85.4 μM. These results indicate substantial heterogeneity within the 5-HT3 antagonist class.

The MATE1 profile was different. Ondansetron was the most potent inhibitor, with an IC50 of 0.1 μM. Palonosetron and tropisetron followed with comparable activity, then granisetron, while dolasetron was the least potent and had an IC50 of 27.4 μM. The reported potency values make ondansetron’s interaction with MATE1 particularly notable relative to its position in the OCT2 ranking.

The directional transport experiments supported the biological significance of these transporter-level observations. Ondansetron reduced basolateral-to-apical ASP+ transport by up to 64% across the tested concentration range. At 10 and 20 μM, palonosetron, tropisetron, and dolasetron also reduced transcellular movement. In the double-transfected OCT2–MATE1 MDCK model, ondansetron at 0.5 and 2.5 μM caused significant intracellular accumulation of ASP+, consistent with impaired efflux through the coordinated secretion pathway.

Mechanistically, intracellular accumulation is an important readout because it suggests that reduced apical transport is not merely an artifact of altered extracellular recovery. If uptake through OCT2 continues while MATE1-mediated extrusion is inhibited, substrate can accumulate within the cell. Conversely, inhibition of basolateral uptake could reduce entry into the cell and produce a different transport phenotype. The study therefore provides a framework for distinguishing transporter bottlenecks.

For pharmacology researchers, the findings support a practical conclusion: antiemetic co-medications may act as perpetrators of renal transporter-mediated interactions with other organic cation drugs. However, the data do not establish that every observed in vitro interaction will produce a clinically meaningful interaction. Translation depends on unbound drug concentrations at the renal transporter sites, dosing schedule, renal function, transporter expression, and the properties of the victim drug.

Comparison with Existing Internal Articles

An internal article on aminoglycoside selection and mechanism addresses a different experimental question: how an antibiotic can support engineered-cell selection and related translational workflows. That article is useful as a contrast, but it should not be treated as evidence for OCT2 or MATE1 inhibition. The reference study concerns renal membrane transport and antiemetic drug interactions, whereas the internal article concerns cell survival under antibiotic selection.

Why this cross-domain matters, maturity, and limitations

The cross-domain distinction matters because both areas involve cell-based assays but use fundamentally different biological endpoints. Transporter studies quantify substrate uptake, efflux, directional movement, and intracellular accumulation. Genetic engineering selection assays instead use differential cellular survival based on expression of a resistance determinant. A compound that inhibits the ribosomal protein synthesis inhibition pathway is not automatically a transporter probe or renal secretion inhibitor.

Accordingly, the connection between these literatures is conceptual and workflow-oriented, not mechanistic evidence that the selection antibiotic changes OCT2 or MATE1 activity. The renal transporter conclusions are supported by the linked reference study; the adjacent cell-engineering context should remain separately validated.

Limitations and Transferability

The most important limitation is that the work is entirely in vitro. Overexpression systems are valuable for assigning transporter interactions, but transporter abundance and membrane localization may differ from those in human proximal tubules. HEK293 and MDCK cells also have distinct background transporters, metabolic capacities, membrane properties, and barrier characteristics.

IC50 values should therefore not be interpreted directly as clinical thresholds. The study does not by itself determine whether therapeutic antiemetic concentrations at the renal basolateral or apical membrane are sufficient to inhibit secretion in patients. Protein binding, active metabolites, renal clearance, disease state, and genetic variation could all modify the magnitude of an interaction.

The ASP+ assay is another consideration. A probe substrate reports transporter function under defined experimental conditions, but its behavior may not match that of every clinically used organic cation. Substrate-dependent inhibition, competitive versus noncompetitive effects, and simultaneous interaction with other transporters may change the response of a different drug.

Future validation should therefore combine transporter-specific assays with physiologically relevant exposure estimates and, where appropriate, clinical pharmacokinetic data. The strongest transferable result from this paper is not a universal ranking of antiemetic risk; it is the methodological principle that OCT2 and MATE1 should be evaluated together when the biological question concerns renal secretion.

Research Support Resources

For adjacent cell-engineering workflows rather than the OCT2/MATE1 experiments described here, researchers can use Geneticin, G-418 Sulfate (SKU A2513) as a genetic engineering selection antibiotic for g418 selection of cells carrying the neomycin resistance gene. The product information describes its activity as a protein synthesis inhibitor targeting the 80S ribosome through a ribosomal protein synthesis inhibition pathway. This application is distinct from renal transporter inhibition and should be validated with an appropriate cell-specific selection protocol.